ELUT Elutia Inc. Class A Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ELUT
—
—
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 26
- List Date
- 2020-10-08
- CIK
- 0001708527
- Next Earnings
- 2026-11-05 (After-Close)
- Headquarters
- Silver Spring, MD
- Homepage
- https://www.elutia.com
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | 44.40% | -5.29% | 63.25% | 34.12% |
| Feb | -- | -1.09% | 18.84% | 12.75% | 10.17% |
| Mar | -- | -10.51% | -19.43% | -7.89% | -12.61% |
| Apr | -- | -10.65% | -7.60% | -6.42% | -8.22% |
| May | -- | 14.04% | -18.55% | 14.85% | 3.45% |
| Jun | -- | 48.06% | 12.50% | -7.58% | 17.66% |
| Jul | -- | -22.01% | -4.69% | -10.66% | -12.45% |
| Aug | -- | 19.88% | 11.76% | -0.32% | 10.44% |
| Sep | 0.46% | -6.16% | -58.88% | -8.25% | -18.21% |
| Oct | -18.75% | -16.45% | 2.73% | -0.25%* | -8.18% |
| Nov | 38.64% | 29.78% | -34.56% | -- | 11.29% |
| Dec | 4.85% | -13.82% | 5.55% | -- | -1.14% |
| Total | 18.65% | 58.09% | -76.14% | 37.26% | 9.47% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.80
SMA 50: $0.84
SMA 200: $0.97
Current: $0.80
EMA 12: $0.81
EMA 26: $0.82
MACD: -0.0027 | Signal: 0.0060
BEARISH
ADX (14): 31.18
TREND
+DI: 9.18
−DI: 19.67
Momentum Oscillators
RSI (14): 47.17
NEUTRAL
Stoch %K: 75.54
Stoch %D: 83.58
Williams %R: -48.35
Volume & Volatility
BB Upper: $0.86
BB Lower: $0.75
NEUTRAL
OBV: -55,428
Vol SMA 20: 467,861
Vol ROC: 87.52%
ATR: $0.07
True Range: $0.10
HV 20: 59.5%
HV 30: 58.5%
HV 60: 61.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: ELUT
Executive Summary
Overall Assessment: NEUTRAL with confidence level (6/10)
Key Drivers:
- Technical indicators suggest a neutral market sentiment, with a mix of bullish and bearish signals.
- Recent news headlines have been primarily neutral, with no significant catalysts.
Primary Risks:
- Low volatility may indicate limited upside potential.
- No earnings data available to assess the company's financial performance.
Investment Thesis: ELUT is currently trading within a range-bound environment, driven by mixed technical signals and neutral news sentiment. The stock's low volatility suggests that it may not be highly sensitive to market movements or news developments. However, the absence of earnings data and significant catalysts means that investors should approach this stock with caution.
Recent News Sentiment Impact: The recent news headlines have been primarily neutral, with no significant impact on the stock's price movement.
Technical Analysis
Trend Direction: Short-term: NEUTRAL (range-bound), Medium-term: BEARISH (slightly), Long-term: BULLISH (moderately)
Support/Resistance Levels:
- Support: $0.78 (lower Bollinger Band), $0.85 (SMA 20)
- Resistance: $1.01 (upper Bollinger Band), $0.94 (SMA 200)
Momentum Signals:
- RSI interpretation: Neutral (46.69) with no clear buy or sell signal.
- MACD signal: Bearish (Histogram: -0.01) with a slight bearish momentum.
- Bollinger Bands position: Neutral (price within the bands).
Volume Analysis: Volume trends suggest a lack of institutional interest, while the On-Balance Volume (OBV) indicates a slight decline in buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: Neutral news headlines with no significant impact on the stock's price movement.
Sentiment Assessment: Neutral sentiment overall, with no clear buy or sell signal.
Catalyst Identification: No upcoming earnings dates or significant regulatory changes announced.
Market Narrative: The neutral market sentiment and lack of institutional interest may suggest a range-bound environment for ELUT.
Risk & Volatility Assessment
Beta Interpretation: Low volatility (beta: 0.18) with a low risk profile compared to the broader market.
Volatility Regime: Current vs historical volatility levels indicate a relatively calm market.
Options Market Signals: No options data available.
Downside Protection: Support levels at $0.78 and $0.85 may provide some protection against potential downside movements.
Market Context & Positioning
Sector Performance: ELUT's performance is neutral compared to its sector.
Institutional Activity: Low institutional interest and volume trends suggest a lack of buying pressure.
Correlation Analysis: The stock moves relatively closely with the market (R-squared: 0.03).
Relative Valuation: ELUT is trading within its historical range, suggesting no clear value or growth opportunities.
Key Levels & Action Items
Critical Price Levels: Support at $0.78 and $0.85, resistance at $1.01 and $0.94.
Breakout/Breakdown Levels: No specific levels identified due to the neutral market sentiment.
Time-Sensitive Catalysts: No upcoming earnings dates or significant regulatory changes announced.
Risk Management: Investors may consider setting stop-loss levels around $0.75, with a target price of $1.05 based on the technical analysis.
This report provides an in-depth analysis of ELUT's current market situation, highlighting both bullish and bearish signals. The neutral market sentiment and low volatility suggest a range-bound environment, which may limit the stock's potential for significant upside or downside movements. Investors should approach this stock with caution, considering the lack of earnings data and significant catalysts.
Generated
News
All ELUT news →
ELUT Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.2628
Alpha: 12.05%
Correlation: 0.0446
R-Squared: 0.2%
Stock Volatility: 75.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ELUT
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $198K | #2883 of 3138 | +144.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $121K | #5700 of 6285 | +10.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ELUT Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
ELUT Insider Trading (Form 4)
Latest: 2026-09-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Matthew Ferguson | CHIEF FINANCIAL OFFICER | Mixed | +8,014 | $0.80 | -$3.6K | EDGAR |
| 2026-09-14 | Michelle LeRoux Williams | CHIEF SCIENTIFIC OFFICER | Mixed | +8,231 | $0.80 | -$3.4K | EDGAR |
| 2026-09-14 | C Randal Mills | PRESIDENT AND CEO | Mixed | +17,365 | $0.80 | -$7.8K | EDGAR |
| 2026-06-22 | C Randal Mills | PRESIDENT AND CEO | Mixed | +14,409 | $1.06 | -$8.5K | EDGAR |
| 2026-06-15 | David Colpman | Director | Grant (A) | +106,393 opt | — | EDGAR | |
| 2026-06-15 | Guido J Neels | Director | Grant (A) | +106,393 opt | — | EDGAR | |
| 2026-06-15 | Brigid Makes | Director | Grant (A) | +106,393 opt | — | EDGAR | |
| 2026-06-15 | Kevin Rakin | Director | Grant (A) | +159,590 opt | — | EDGAR | |
| 2026-06-12 | Matthew Ferguson | CHIEF FINANCIAL OFFICER | Mixed | +8,015 | $1.04 | -$4.7K | EDGAR |
| 2026-06-12 | Michelle LeRoux Williams | CHIEF SCIENTIFIC OFFICER | Mixed | +8,231 | $1.04 | -$4.4K | EDGAR |
| 2026-06-12 | C Randal Mills | PRESIDENT AND CEO | Mixed | +17,365 | $1.04 | -$10.1K | EDGAR |
| 2026-06-02 | HighCape Partners QP II, L.P. | 10%+ Owner | Mixed | −480,000 | — | EDGAR | |
| 2026-04-14 | Guido J Neels | Director | Exer (M) | +6,250 | — | EDGAR | |
| 2026-03-12 | C Randal Mills | PRESIDENT AND CEO | Mixed | +15,984 | $1.09 | -$12.1K | EDGAR |
| 2026-03-12 | Michelle LeRoux Williams | CHIEF SCIENTIFIC OFFICER | Mixed | +7,887 | $1.09 | -$5.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ELUT Insider Holdings
12 insiders · @ $0.80
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | HighCape Partners GP, LLC | 10%+ Owner | 9,520,232 | $7.60M | $10.50M | 1 | 2025-03-13 |
| 2 | HighCape Capital, L.P. | Director | 9,520,232 | $7.60M | $2.10M | 1 | 2025-03-13 |
| 3 | HIGHCAPE PARTNERS QP, L.P. | 10%+ Owner | 5,105,098 | $4.07M | $0 | 2 | 2025-12-19 |
| 4 | HighCape Partners QP II, L.P. | 10%+ Owner | 4,832,679 | $3.86M | $0 | 1 | 2026-06-02 |
| 5 | HighCape Partners GP II, LLC | 10%+ Owner | 4,832,679 | $3.86M | $104.0K | 2 | 2025-12-19 |
| 6 | Kevin Rakin | Director | 518,539 | $413.8K | $296.8K | 6 | 2026-06-15 |
| 7 | Matthew Ferguson | CHIEF FINANCIAL OFFICER | 489,903 | $390.9K | $38.4K | 18 | 2026-09-14 |
| 8 | C Randal Mills | PRESIDENT AND CEO | 464,395 | $370.6K | $14.6K | 19 | 2026-09-14 |
| 9 | Michelle LeRoux Williams | CHIEF SCIENTIFIC OFFICER | 130,552 | $104.2K | $0 | 13 | 2026-09-14 |
| 10 | Guido J Neels | Director | 125,000 | $99.8K | $52.6K | 6 | 2026-06-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ELUT Board & Officers
As of SEC filings through Sep 14, 2026Directors 6
- Brigid Makes · since Oct 7, 2020
- C Randal Mills · since Oct 7, 2020
- Kevin Rakin · since Oct 7, 2020
- Maybelle Jordan · since Oct 7, 2020
- David Colpman · since Oct 20, 2022
- Guido J Neels · since Oct 9, 2025
Officers 3
- C Randal Mills · President and CEO · listed since Apr 2023
- Matthew Ferguson · Chief Financial Officer · since Oct 7, 2020
- Michelle LeRoux Williams · Chief Scientific Officer · since Aug 22, 2022
10% owners 11
- HighCape Co-Investment Vehicle I, LLC (entity) · since Oct 7, 2020
- HighCape Co-Investment Vehicle II, LLC (entity) · since Oct 7, 2020
- HighCape Partners GP II, L.P. (entity) · since Dec 5, 2022
- HighCape Partners GP II, LLC (entity) · since Dec 5, 2022
- HighCape Partners GP, L.P. (entity) · since Oct 7, 2020
- HighCape Partners GP, LLC (entity) · since Oct 7, 2020
- HighCape Partners QP II, L.P. (entity) · since Dec 5, 2022
- Highcape Partners Qp, L.p. (entity) · since Oct 7, 2020
- Highcape Partners, L.p. (entity) · since Oct 7, 2020
- Kevin Rakin · since Oct 7, 2020
- Matt Zuga · since Oct 7, 2020
Changes in the last 10 years (59)
| Oct 9, 2025 | Guido J Neels became a director |
| Oct 7, 2025 | The company announced the departure of Matt Zuga from the board in an SEC filing |
| Feb 20, 2024 | Matthew Strobeck no longer listed as a 10% owner in SEC filings |
| Feb 20, 2024 | Birchview Fund LLC no longer listed as a 10% owner in SEC filings |
| Feb 20, 2024 | Birchview Capital, LP no longer listed as a 10% owner in SEC filings |
| Oct 5, 2023 | Highcape Partners, L.p. no longer listed as a director in SEC filings |
| Oct 5, 2023 | Highcape Partners Qp, L.p. no longer listed as a director in SEC filings |
| Oct 5, 2023 | HighCape Partners GP, LLC no longer listed as a director in SEC filings |
| Oct 5, 2023 | HighCape Partners GP, L.P. no longer listed as a director in SEC filings |
| Oct 5, 2023 | HighCape Co-Investment Vehicle II, LLC no longer listed as a director in SEC filings |
| Oct 5, 2023 | HighCape Co-Investment Vehicle I, LLC no longer listed as a director in SEC filings |
| Oct 5, 2023 | HighCape Capital, LLC no longer listed as a director in SEC filings |
| Sep 21, 2023 | Elutia PIPE Investment, LP became a 10% owner |
| Jun 12, 2023 | Highcape Partners, L.p. first listed as a director in an SEC filing |
| Jun 12, 2023 | Highcape Partners Qp, L.p. first listed as a director in an SEC filing |
| Jun 12, 2023 | HighCape Partners GP, LLC first listed as a director in an SEC filing |
| Jun 12, 2023 | HighCape Partners GP, L.P. first listed as a director in an SEC filing |
| Jun 12, 2023 | HighCape Co-Investment Vehicle I, LLC first listed as a director in an SEC filing |
| Jun 12, 2023 | HighCape Capital, LLC first listed as a director in an SEC filing |
| Apr 28, 2023 | C Randal Mills listed as President and CEO (previously Interim President and CEO) in SEC filings |
| Dec 5, 2022 | HighCape Partners QP II, L.P. became a 10% owner |
| Dec 5, 2022 | HighCape Partners II, L.P. became a 10% owner |
| Dec 5, 2022 | HighCape Partners GP II, LLC became a 10% owner |
| Dec 5, 2022 | HighCape Partners GP II, L.P. became a 10% owner |
| Oct 20, 2022 | David Colpman became a director |
| Aug 22, 2022 | Michelle LeRoux Williams became Chief Scientific Officer |
| Jun 23, 2022 | C Randal Mills first listed as Interim President and CEO in an SEC filing |
| Jun 20, 2022 | The company announced the departure of Ronald K. Lloyd from the board in an SEC filing |
| Jun 20, 2022 | The company announced the departure of Ronald K. Lloyd as President and CEO in an SEC filing |
| Dec 5, 2021 | Matthew Strobeck became a 10% owner |
| Dec 5, 2021 | Birchview Fund LLC became a 10% owner |
| Dec 5, 2021 | Birchview Capital, LP became a 10% owner |
| Aug 31, 2021 | Peter G Edwards became General Counsel |
| Jun 9, 2021 | HighCape Co-Investment Vehicle II, LLC first listed as a director in an SEC filing |
| Jun 9, 2021 | HighCape Capital, L.P. first listed as a director in an SEC filing |
| Mar 10, 2021 | Darryl Roberts listed as EVP, Operations & Product Dev. (previously EVP and General Manager, Muscu) in SEC filings |
| Oct 7, 2020 | Thomas Englese became Chief Commercial Officer |
| Oct 7, 2020 | Ronald K. Lloyd became a director |
| Oct 7, 2020 | Ronald K. Lloyd became President and CEO |
| Oct 7, 2020 | Maybelle Jordan became a director |
| Oct 7, 2020 | Matthew Ferguson became Chief Financial Officer |
| Oct 7, 2020 | Matt Zuga became a director |
| Oct 7, 2020 | Matt Zuga became a 10% owner |
| Oct 7, 2020 | Kevin Rakin became a director |
| Oct 7, 2020 | Kevin Rakin became a 10% owner |
| Oct 7, 2020 | Keralink International, Inc. became a 10% owner |
| Oct 7, 2020 | Jerome Riebman became Chief Medical Officer |
| Oct 7, 2020 | Highcape Partners, L.p. became a 10% owner |
| Oct 7, 2020 | Highcape Partners Qp, L.p. became a 10% owner |
| Oct 7, 2020 | HighCape Partners GP, LLC became a 10% owner |
| Oct 7, 2020 | HighCape Partners GP, L.P. became a 10% owner |
| Oct 7, 2020 | HighCape Co-Investment Vehicle II, LLC became a 10% owner |
| Oct 7, 2020 | HighCape Co-Investment Vehicle I, LLC became a 10% owner |
| Oct 7, 2020 | HighCape Capital, LLC became a 10% owner |
| Oct 7, 2020 | HighCape Capital, L.P. became a 10% owner |
| Oct 7, 2020 | Darryl Roberts became EVP and General Manager, Muscu |
| Oct 7, 2020 | Cormatrix Cardiovascular Inc became a 10% owner |
| Oct 7, 2020 | C Randal Mills became a director |
| Oct 7, 2020 | Brigid Makes became a director |
Not reported recently (10)
- HighCape Capital, LLC · Last reported as a 10% owner in an SEC filing dated Mar 13, 2025
- HighCape Capital, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 13, 2025
- HighCape Partners II, L.P. · Last reported as a 10% owner in an SEC filing dated Aug 1, 2024
- Elutia PIPE Investment, LP · Last reported as a 10% owner in an SEC filing dated Oct 5, 2023
- Thomas Englese · Last reported as Chief Commercial Officer in an SEC filing dated Mar 9, 2023
- Jerome Riebman · Last reported as Chief Medical Officer in an SEC filing dated Sep 12, 2022
- Peter G Edwards · Last reported as General Counsel in an SEC filing dated Sep 12, 2022
- Darryl Roberts · Last reported as EVP, Operations & Product Dev. in an SEC filing dated Mar 10, 2022
- Cormatrix Cardiovascular Inc · Last reported as a 10% owner in an SEC filing dated Oct 7, 2020
- Keralink International, Inc. · Last reported as a 10% owner in an SEC filing dated Oct 7, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ELUT Proposed Insider Sales (Form 144)
Latest: 2025-12-23
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-12-23 | William Matthew Zuga | Former Director | 12,613 | $6.9K | 2025-12-23 | APEX CLEARING350 N ST. PAUL ST | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
3 ETFs hold ELUT
3 shown · $1.01M total exposure · 0.01% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.